Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pirinixic Acid (NSC 310038) is a synthetic thiacetic acid derivative used in biomedical research, carcinogenic Pirinixic acid is a peroxisome proliferator that activates specific peroxisome proliferator-activated receptors (PPAR).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
10 mg | In stock | $ 41.00 | |
25 mg | In stock | $ 58.00 | |
50 mg | In stock | $ 72.00 | |
100 mg | In stock | $ 107.00 | |
200 mg | In stock | $ 151.00 | |
500 mg | In stock | $ 249.00 | |
1 g | In stock | $ 369.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 39.00 |
Description | Pirinixic Acid (NSC 310038) is a synthetic thiacetic acid derivative used in biomedical research, carcinogenic Pirinixic acid is a peroxisome proliferator that activates specific peroxisome proliferator-activated receptors (PPAR). |
Targets&IC50 | PPARα:1.5 μM(EC50) |
In vitro | WY14643 significantly reduced visceral fat mass and total liver triglyceride content without increasing body weight. It enhanced systemic insulin sensitivity and improved insulin-mediated skeletal muscle glucose metabolism in both red (47%) and white (63%) muscle fibers, as well as in white adipose tissue (90%), while reducing muscle triglyceride and LCACoA accumulation. Administration of WY14643 (1 mg/kg i.v.) 30 minutes before left anterior descending artery occlusion led to a notable reduction in infarct size (~44%) in rats subjected to myocardial ischemia (25 minutes) followed by reperfusion (2 hours). In rats fed a high-fat diet, treatment with 3 mg/kg WY14643 lowered plasma glucose and triglyceride levels (-16% vs. untreated), leptin (-52%), muscle triglycerides (-34%), and overall long-chain acyl-coenzyme A (-41%) levels. |
In vivo | WY14643 (250 μM) significantly reduces the expression levels of VCAM-1, lowering it to 52% of those in human endothelial cells stimulated by TNF-α. At a concentration of 10 μM, WY 14643 acts on aortic smooth muscle cells to almost completely inhibit the production of IL-6 and prostaglandin induced by IL-1, as well as the expression of cyclooxygenase-2, through the suppression of the NF-κB signaling pathway. Pre-treating endothelial cells with WY 14643 (10 μM) before TNF-α stimulation decreases U937 cell adhesion by 50%. |
Kinase Assay | Fluorescence Polarization Assay: Binding of HSP90 inhibitors to human full-length recombinant HSP90β is determined by a competitive binding fluorescence polarization assay, using a fluorescent pyrazole resorcinol probe. |
Synonyms | Wy-14643, NSC 310038 |
Molecular Weight | 323.8 |
Formula | C14H14ClN3O2S |
CAS No. | 50892-23-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 32.4 mg/mL (100 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Pirinixic Acid 50892-23-4 DNA Damage/DNA Repair Metabolism PPAR Wy 14643 Wy-14643 Wy14643 NSC310038 NSC 310038 Peroxisome proliferator-activated receptors inhibit NSC-310038 Inhibitor inhibitor